European Pharma Gains Attention#
The European pharmaceutical sector is gaining renewed interest as a defensive investment choice. Bernstein, a well-known brokerage, has identified three stocks that stand out due to their promising pipelines, potential for earnings upgrades, and catalysts for re-evaluation. These stocks are expected to see price increases of 36% to 53% based on Bernstein's analysis.
AstraZeneca: A Strong Large-Cap Choice#
AstraZeneca is highlighted as Bernstein's top pick among large-cap stocks. Analysts believe there is significant potential for earnings per share (EPS) upgrades, particularly from its non-cancer drug pipeline, which they feel is undervalued by the market. The company has four important clinical trial results expected in 2026-2027, including a program for a rare cardiac disease that could generate substantial sales. Bernstein considers AstraZeneca one of the most affordable high-quality research and development (R&D) firms in global pharmaceuticals, projecting a 35% premium compared to its European competitors.
GSK: A Transformative Player#
GSK is ranked second among large-cap stocks. Bernstein praises the company’s current chief executive for fostering innovation, suggesting that GSK could see up to a 27% increase in EPS. A key upcoming event is the phase 3 trial results for a treatment for chronic cough, which could act as a catalyst for growth. Analysts note that GSK's current valuation is lower than its European peers, despite the company's ambitious sales target of over £40 billion by 2031, which exceeds the consensus estimate of £36 billion.
Argenx: A High-Conviction Bet#
Argenx stands out as Bernstein's most confident recommendation across all covered stocks. This Belgian company specializes in immunology and has four major clinical trial results expected by the end of 2027. Analysts believe Argenx is undervalued compared to its U.S. biotech counterparts. Bernstein appreciates the company's proactive approach to diversifying its pipeline, which reduces the risk of relying on a single product, especially as patents expire in the future.